Royalty Report: Drugs, Cancer, Therapeutic – Collection: 172894

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Drugs
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Gastrointestinal
  • Pain
  • Diagnostic
  • Alzheimer’s disease
  • Nerve
  • Radiation
  • Lighting

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 172894

License Grant
The University and Licensee hereby agree to amend the License Agreement to reduce the earned royalties  payable on sublicense income,  and to make certain other changes to the License Agreement whereas the University and Licensee are parties to a License  Agreement, under which the University exclusively licensed to Licensee a series of University owned inventions relating to potential gene therapy vectors.
License Property
Patent Listing

US Patent Number 5,101,072, Issued 3/3/1992

N-methyl and N-(2-Clorethyl) sulfonylhydrazines as Antineoplastic and Antitrypanosomal Agents

US Patent Number 5,214,068, Issued 5/25/1993

Sulfonylhydrazines and Their Use as Antineoplastic Agents and as Antitrypanosomal Agents

US Patent Number 5,256,820, Issued 10/26/1993

1-Alkyl-2-Acyl-1, 2-Disulfonylhydrazines

Additional Technologies

Antitumor 2-2 -aminocarbonyl -1-1, 2-bis (methylsulfonyl) -1-2-chloroethyl) ydrazines; (OCR 512)

2-Alkoxcarbonyl-and 2-aryloxycarbonyl -1, 2-bis (methylsulfonyl) – 1- (2chloroethyl) hyrazines with Antineoplastic Activity (OCR 524)

Synthesis of 3- and 5-methylaminopyridine-2 -carboxaldehyde Thiosemicarbazones (OCR 527)

Synthesis and Antitumor Active of 4- and 5-Substituted Derivatives of Isoquinoline-1-carboxaldehyde Thiosemicarbazone (OCR 528)

US Patent Application Serial Number 098,650

Novel L-2', 3'-Dideoxy Nucleoside Analogs as Anti-Hepatitis B (HBV) Agents

Additional Technology

Inhibition of Human Hepatitis B virus Replication by 3'-Thia 2', 3'-dideoxycytidine and its Derivatives (OCR 340)

Use of Porfiromycin, Dicoumoral, and X-irradiation for the treatment of solid tumors in Humans (CR 74)

Access to certain Data Concerning Clinical Studies carried out under the supervision of Yale faculty Concerning Porfiromycin

Licensed Products shall mean all products for therapeutic or diagnostic uses that may derive from or which result from the manufacture and production or use of a claim of the Licensed Patents, wherever sold.

Technology is relative to Anti-Hepatitis B Agents and treatment of solid tumors in humans.

Term Agreement lasts through expiration of last patent.

Territory Worldwide

5,101,072 The present invention is directed to novel sulfonylhydrazines and their use as antineoplastic agents. The present invention also concerns methylating agents, especially N-methyl-N- sulfonylhydrazines, and their use as antineoplastic and trypanocidal agents.  The present invention also relates to a method of treating cancer (e.g., leukemia, lymphoma, breast carcinoma, colon carcinoma and lung carcinoma), in a warm blooded animal patient, e.g., a human, by administering to such patient an antineoplastic effective amount of the aforesaid sulfonylhydrazine.

5,256,820 This invention generally concerns compounds having antineoplastic activity and methods of therapy using these compounds.

5,101,072 Sulfonylhydrazines of the formula RSO.sub.2 N(CH.sub.2 CH.sub.2 X)N(SO.sub.2 CH.sub.3).sub.2, wherein R is an alkyl or an aryl and X is a halogen or OSO.sub.2 Y, wherein Y is an alkyl or an aryl. Such sulfonylhydrazines are useful in treating cancer. Methylating agents of the formula (a) R'SO.sub.2 N(CH.sub.3)N(SO.sub.2 CH.sub.3).sub.2, wherein R' is an alkyl or an aryl and (b) R'SO.sub.2 N(CH.sub.3)N(CH.sub.3)SO.sub.2 R, wherein R is an alkyl or an aryl. Such methylating agents are useful as antitrypanosomal and anticancer agents.

5,256,820  Novel antineoplastic 1-alkyl-2-acyl-1,2-disulfonylhydrazine having the following formula and methods of therapy using those antineoplastic compounds ##STR1## where R.sub.1 and R.sub.2 are (independently) alkyl, cycloalkyl, aryl, aralkyl or heteroaryl. X is an acyl group, and Z is an alkyl or a haloalkyl group.

Field of Use
This agreement pertains to the drug industry relating to gene therapy vectors.

Technology is relative to Anti-Hepatitis B Agents and treatment of solid tumors in humans.

IPSCIO Record ID: 26805

License Grant
License grants a non-transferable worldwide exclusive license to a U.S. corporation from a U.S. University. Technology licensed includes the following US Patent Number 5,101,072, Issued 3/3/1992 N-methyl and N-(2-Clorethyl) sulfonylhydrazines as Antineoplastic and Antitrypanosomal Agents.
License Property
Patent Listing

US Patent Number 5,101,072, Issued 3/3/1992

N-methyl and N-(2-Clorethyl) sulfonylhydrazines as Antineoplastic and Antitrypanosomal Agents

US Patent Number 5,214,068, Issued 5/25/1993

Sulfonylhydrazines and Their Use as Antineoplastic Agents and as Antitrypanosomal Agents

US Patent Number 5,256,820, Issued 10/26/1993

1-Alkyl-2-Acyl-1, 2-Disulfonylhydrazines

Additional Technologies

Antitumor 2-2 -aminocarbonyl -1-1, 2-bis (methylsulfonyl) -1-2-chloroethyl) ydrazines; (OCR 512)

2-Alkoxcarbonyl-and 2-aryloxycarbonyl -1, 2-bis (methylsulfonyl) – 1- (2chloroethyl) hyrazines with Antineoplastic Activity (OCR 524)

Synthesis of 3- and 5-methylaminopyridine-2 -carboxaldehyde Thiosemicarbazones (OCR 527)

Synthesis and Antitumor Active of 4- and 5-Substituted Derivatives of Isoquinoline-1-carboxaldehyde Thiosemicarbazone (OCR 528)

US Patent Application Serial Number 098,650

Novel L-2', 3'-Dideoxy Nucleoside Analogs as Anti-Hepatitis B (HBV) Agents

Additional Technology

Inhibition of Human Hepatitis B virus Replication by 3'-Thia 2', 3'-dideoxycytidine and its Derivatives (OCR 340)

Use of Porfiromycin, Dicoumoral, and X-irradiation for the treatment of solid tumors in Humans (CR 74)

Access to certain Data Concerning Clinical Studies carried out under the supervision of Yale faculty Concerning Porfiromycin

Licensed Products shall mean all products for therapeutic or diagnostic uses that may derive from or which result from the manufacture and production or use of a claim of the Licensed Patents, wherever sold.

Field of Use
Technology is relative to Anti-Hepatitis B Agents and treatment of solid tumors in humans.

IPSCIO Record ID: 26815

License Grant
The University hereby grants to Licensee, subject to all the terms and conditions of this Agreement, a non-transferable worldwide exclusive license for the term defined by this agreement to make, have made, use, sell and practice the inventions and to commercialize the research, in each case for therapeutic or diagnostic purposes.
License Property
Licensed Products shall mean all products for therapeutic or diagnostic uses that may derive from or which result from the manufacture and production or use of a claim of the licensed patents, wherever sold.

The Licensed Patents involved are as follows

US Patent Number 5,101,072, Issued 3/3/1992 N-methyl and N-(2-Clorethyl) sulfonylhydrazines as Antineoplastic and Antitrypanosomal Agents
US Patent Number 5,214,068, Issued 5/25/1993 Sulfonylhydrazines and Their Use as Antineoplastic Agents and asAntitrypanosomal Agents
US Patent Number 5,256,820, Issued 10/26/1993 1-Alkyl-2-Acyl-1, 2-Disulfonylhydrazines

Additional Technologies Antitumor 2-2 -aminocarbonyl -1-1, 2-bis (methylsulfonyl) -1-2-chloroethyl) hydrazines; (OCR 512)
2-Alkoxcarbonyl-and 2-aryloxycarbonyl -1, 2-bis (methylsulfonyl) – 1-
(2chloroethyl) hyrazines with Antineoplastic Activity (OCR 524)
Synthesis of 3- and 5-methylaminopyridine-2 -carboxaldehyde Thiosemicarbazones (OCR 527)
Synthesis and Antitumor Active of 4- and 5-Substituted Derivatives of Isoquinoline-1-carboxaldehyde Thiosemicarbazone (OCR 528)
US Patent Application Serial Number 098,650 Novel L-2', 3'-Dideoxy Nucleoside Analogs as Anti-Hepatitis B (HBV) Agents
Additional Technology
Inhibition of Human Hepatitis B virus Replication by 3'-Thia 2', 3'-dideoxycytidine and its Derivatives (OCR 340)

IPSCIO Record ID: 28322

License Grant
Licensor hereby grants to Licensee and its Affiliates a sole and exclusive worldwide sublicense in all fields of use to practice under the Patent Rights and to utilize the Know-how, and to make, have made, use, lease and/or sell the Licensed Products and to practice the Licensed Processes, to the full end of the term for which the Patent Rights are granted, unless sooner terminated as hereinafter provided.
License Property
Patent(s) or Patent Application(s)

U.S. Application Serial No. 07/492,468 filed 3/13/90; “06-Substituted Guanine Compounds And Methods For Depleting 06-Alkylguanine-DNA Alkyltransferase Levels” Issued 2/25/92 U.S. Pat. 5,091,430

U.S. Application Serial No. 07/616,913 filed 11/21/90; “06-Benzylated Guanine, Guanosine and 2’-Deoxyguanosine Compounds Possessing 06-Alkylguanine-DNA Alkyltransferase Depleting Activity” CIP of ‘468 issued 10/4/94 U.S. Pat. 5,352,669

U.S. Application Serial No. 07/805,634 filed 12/21/91; “06-Substituted Guanine Compounds And Methods For Depleting 06-Alkylguanine-DNA Alkyltransferase Levels” DIV of ‘468, issued 10/25/94 U.S. Pat. 5,358,952

U.S. Application Serial No. 07/875,438 filed 4/29/92; “06-Substituted Guanine Compounds and Methods for Depleting Derivatives 06 Alkylguanine-DNA Alkyltransferase Levels” CIP of ‘634 Abandoned 8/19/94

U.S. Application Serial No. 08/255,190 filed 6/7/94; “06-Substituted Guanine Compounds And Methods For Depleting 06-Alkylguanine-DNA Alkyltransferase” CIP of ‘438, and ‘913 issued 11/25/97 U.S. Pat. 5691,307.

U.S. Application Serial No. 08/283,953 filed 8/1/94; “Substituted 06-Benzylguanines And 6(4) – Benzyloxpyrimidines” issued 6/11/96 U.S. Pat. 5,525,606, and PCT/US95/09702 filed 7/31/95 (based on parent application 08/283.953.  National Stage filed in Europe (EPO Application No. 9592837.7.  Validated in all countries, except Finland, under the European Patent Convention), Canada (Canadian Application No. 2,195,856), Japan (Japanese Application No. 506694/1996), Australia (Australian Serial No. 32079/95, Issued Patent No. 702711) and U.S. Application No. 08/849,223, Issued 9/28/99 as U.S. Patent No. 5,958,932).  Divisional of EP ‘837.7, Application No. 01108585.9 filed 4/5/01.

U.S. Application Serial No. 08/661,923 filed 6/11/96, issued 5/19/98 as 5,753,668; “Substituted  Benzyloxpyrimidines and Their Inactivation of 06-Alkylguanine-DNA Alkyltransferase” DIV of parent application 08/283.953.

U.S. Application Serial No. 08/927, 846 filed 9/11/97. Issued 6/29/99 as 5,916,894; “Substituted O6-Benzylguanines And 6(4) – Benzyloxpyrimidines” DIV of parent application 08/283,953.

U.S. Application Serial No. 08/318,238 filed 5/25/99. Issued 1/9/01 as 6,172,070; “Substituted O6-Benzylguanines And 6(4) – Benzyloxpyrimidines” DIV of parent application 08/283.953.

U.S. Application Serial No. 08/849,223 filed 7/31/95. Issued  9/28/99 as 5,958,932; “Substituted O6-Benzylguanines And 6(4) – Benzyloxpyrimidines” CIP of parent application 08/283,953.

U.S. Application  No. 09/590,187, filed 6/9/00, U.S Patent 6,303,604, issued 10/16/01U.S. Application Serial No. 09/333,047 filed 6/15/99 (Allowed) “Pharmaceutical Composition Comprising 2,4-Diamino-6-Benzyloxy-Triazine And Inactivation of O6-Alkylguanine-DNA-Alkyltransferase.”

U.S. Application No. 09/333,047, filed 6/15/99, U.S Patent 6,333,331, issued 12/25/01 “Substituted 06-Benzylguanines.”

U.S. Application No. 09/928,410; filed 8/14/01 “Substituted 06 Benzyl-8-Aza-Guanines” Pending.

Field of Use
The following will serve to outline License’s (the 'Sublicensee') plans for development of O6-Benzylguanine ('BG') as an intravenous chemotherapeutic potentiating agent used in combination with alkylating agents such as BCNU or Temozolomide (the 'Agent' or 'Agents') for the treatment of cancer.

IPSCIO Record ID: 27804

License Grant
Licensor, government organization, hereby grants and Licensee accepts, subject to the terms and conditions of this Agreement, an exclusive license under the Licensed Patent Rights in the Licensed Territory to make and have made, to use and have used, to sell and have sold, to offer to sell, and to import any Licensed Products in the Licensed Fields of Use and to practice and have practiced any Licensed Processes in the Licensed Fields of Use.
License Property
Patent(s) or Patent Application(s)

U.S. Application Serial No. 07/492,468 filed 3/13/90; “06-Substituted Guanine Compounds And Methods For Depleting 06-Alkylguanine-DNA Alkyltransferase Levels” Issued 2/25/92 U.S. Pat. 5,091,430

U.S. Application Serial No. 07/616,913 filed 11/21/90; “06-Benzylated Guanine, Guanosine and 2’-Deoxyguanosine Compounds Possessing 06-Alkylguanine-DNA Alkyltransferase Depleting Activity” CIP of ‘468 issued 10/4/94 U.S. Pat. 5,352,669

U.S. Application Serial No. 07/805,634 filed 12/21/91; “06-Substituted Guanine Compounds And Methods For Depleting 06-Alkylguanine-DNA Alkyltransferase Levels” DIV of ‘468, issued 10/25/94 U.S. Pat. 5,358,952

U.S. Application Serial No. 07/875,438 filed 4/29/92; “06-Substituted Guanine Compounds and Methods for Depleting Derivatives 06 Alkylguanine-DNA Alkyltransferase Levels” CIP of ‘634 Abandoned 8/19/94

U.S. Application Serial No. 08/255,190 filed 6/7/94; “06-Substituted Guanine Compounds And Methods For Depleting 06-Alkylguanine-DNA Alkyltransferase” CIP of ‘438, and ‘913 issued 11/25/97 U.S. Pat. 5691,307.

U.S. Application Serial No. 08/283,953 filed 8/1/94; “Substituted 06-Benzylguanines And 6(4) – Benzyloxpyrimidines” issued 6/11/96 U.S. Pat. 5,525,606, and PCT/US95/09702 filed 7/31/95 (based on parent application 08/283.953.  National Stage filed in Europe (EPO Application No. 9592837.7.  Validated in all countries, except Finland, under the European Patent Convention), Canada (Canadian Application No. 2,195,856), Japan (Japanese Application No. 506694/1996), Australia (Australian Serial No. 32079/95, Issued Patent No. 702711) and U.S. Application No. 08/849,223, Issued 9/28/99 as U.S. Patent No. 5,958,932).  Divisional of EP ‘837.7, Application No. 01108585.9 filed 4/5/01.

U.S. Application Serial No. 08/661,923 filed 6/11/96, issued 5/19/98 as 5,753,668; “Substituted  Benzyloxpyrimidines and Their Inactivation of 06-Alkylguanine-DNA Alkyltransferase” DIV of parent application 08/283.953.

U.S. Application Serial No. 08/927, 846 filed 9/11/97. Issued 6/29/99 as 5,916,894; “Substituted O6-Benzylguanines And 6(4) – Benzyloxpyrimidines” DIV of parent application 08/283,953.

U.S. Application Serial No. 08/318,238 filed 5/25/99. Issued 1/9/01 as 6,172,070; “Substituted O6-Benzylguanines And 6(4) – Benzyloxpyrimidines” DIV of parent application 08/283.953.

U.S. Application Serial No. 08/849,223 filed 7/31/95. Issued  9/28/99 as 5,958,932; “Substituted O6-Benzylguanines And 6(4) – Benzyloxpyrimidines” CIP of parent application 08/283,953.

U.S. Application  No. 09/590,187, filed 6/9/00, U.S Patent 6,303,604, issued 10/16/01U.S. Application Serial No. 09/333,047 filed 6/15/99 (Allowed) “Pharmaceutical Composition Comprising 2,4-Diamino-6-Benzyloxy-Triazine And Inactivation of O6-Alkylguanine-DNA-Alkyltransferase.”

U.S. Application No. 09/333,047, filed 6/15/99, U.S Patent 6,333,331, issued 12/25/01 “Substituted 06-Benzylguanines.”

U.S. Application No. 09/928,410; filed 8/14/01 “Substituted 06 Benzyl-8-Aza-Guanines” Pending.

Field of Use
Licensed Fields of Use Development and administration of 06-Benzylated Guanine and Derivatives thereof to enhance chemotherapy treatments of tumor cells.

IPSCIO Record ID: 516

License Grant
The Netherlands company grants the Licensee the right to a sole and exclusive License to sell compounds derived from the compounds known as Indoloquinones to all markets in the World, hereinafter called the market.
License Property
The antitumor activity of the compounds has been evaluated by cancer research institutes.  Patent Number P5079257.
Field of Use
The rights granted apply to cancer research.

IPSCIO Record ID: 230800

License Grant
The German Licensor hereby grants to Licensee the exclusive (even as to Licensor) right and license under the Licensor Patents and the Licensor Know-how to Develop and Commercialize the Product in the Territory and within the Field, subject to the terms and conditions hereof.

The granting of sublicenses by Licensee under the licenses set forth in this Agreement to Affiliates of Licensee or any Third Party shall be subject to Licensor’s prior written consent; such consent not to be unreasonably withheld.

License Property
Product means any pharmaceutical product for inhaled use which includes, as an active ingredient the Substance.

Drug Product shall mean the pharmaceutical product for inhaled use which includes, as an active ingredient, the Substance, and complies with the relevant Specifications.

Licensor Patents means any Patents in the Territory owned or Controlled by Licensor or its Affiliates as of the Effective Date or which comes within the ownership or Control of Licensor or any of its Affiliates during the term of this Agreement covering the Development, Manufacture, or Commercialization of the Substance, the Drug Substance, the Drug Product or the Product in the Field.

US 4,692,464 – Novel prostacyclin derivatives and a process for the preparation thereof
US 4,894,336 – Racemic dissociation of 3-acyloxy bicyclo(3.3.0)octan-7-one-2-carboxylic acid esters by stereospecific enzymatic or microbiological acylate hydrolysis
US 5,200,530 – The invention relates to a new process for the reduction of 15-keto carbacyclin intermediates in the presence of cerium(III) Salts.

Patents means all patents, patent applications and patent applications hereinafter filed in any country of the world, including any continuation, continuation-in-part, division, provisional or any substitute applications, any patent issued with respect to any such patent applications, any reissue, reexamination, renewal or extension (including any supplemental patent certificate) of any such patent, and any confirmation patent or registration patent or patent of addition based on any such patent, and all foreign counterparts of any of the foregoing.

Licensor Know-how means Know-how within the Control of Licensor as of the Effective Date or which comes within the Control of Licensor during the term of this Agreement and relates to the Development, Manufacture or Commercialization of the Substance, the Drug Substance, the Drug Product or the Product in the Field in the Territory. Notwithstanding anything herein to the contrary, Licensor Know-how shall exclude Licensor Patents.

Field of Use
Field means inhaled use of the Substance and/or Product in the indication “pulmonary hypertension” in humans.

IPSCIO Record ID: 169272

License Grant
In this agreement where Licensee is the principal stockholder of Licensor, Licensor shall grant to Licensee a worldwide sublicense to practice under the Patent Rights , and to make, have made, use, lease and/or sell the Licensed Products in the Licensee Field and to practice the Licensed Processes in the Licensee Field, said sublicense to include the right to subsublicense in the Licensee Field and to be exclusive to Licensee in the Licensee Field.
License Property
These Patent Rights are licensed to the Licensor pursuant to the terms of a License Agreement dated as of October 31, 1992.

Licensee at its own expense and utilizing patent counsel of its choice shall have the sole right and responsibility for the prosecution and maintenance of the Nudelman Patent, provided that Licensee shall not take any action with respect to the Nudelman Patent that could result in any diminution of rights relating to the composition of matter claims relating to AN10.  Licensor shall have the sole right and responsibility for the prosecution and  maintenance of the Hemoglobinopathies Patent.

Hemoglobinopathies Patent shall mean issued U.S. Patent No. 5,569,675 and any related foreign patent applications or patents, including any continuations, continuations-in-part, divisional, reissues, reexaminations or extensions thereof.

Nudelman Patent shall mean issued U.S. Patent No. 5,200,553 and any related foreign patent applications or patents, including any continuations, continuations-in-part, divisional, reissues, reexaminations or extensions thereof.

AN 10 shall mean butylidene dibutyrate.

Field of Use
This agreement pertains to the drug industry relating to the field (a) with respect to all compounds except AN  10, all indications except (i) those covered by the Hemoglobinopathies Patent and (ii) topical applications (other than oncologic disorders) and (b) with respect to AN 10, non-topical applications for oncologic disorders.

IPSCIO Record ID: 203384

License Grant
The University grants an exclusive, worldwide right and license, with the right to grant Sublicenses and to permit Sub-sublicenses to practice under and use the Licensed Patents and the Licensed Technology to make, have made, use, market, sell, have sold, import, distribute, and offer for sale any Licensed Product, Licensed Process or Generic Product.
License Property
The Licensed Technology shall mean any technology, trade secrets, methods, processes, know-how, show-how, data, information, or results relating to Licensor items developed by the Contributors, and owned by Licensor, including  agents, compositions, compounds, or analogs or isomers thereof, of nonsteroidal molecules which bind to androgen receptors, including radiolabeled, fluorescent, and radioisotopes incorporated thereto and small molecules of R-bicalutamide, androgen receptor targeting agents, oral testosterone compositions;  methods of making developing, or characterizing such agents, compositions, and composition, compounds; and  any therapeutic, diagnostic, and prognostic methods of use, of such compounds or agents, including but not limited to methods of treating prostate cancer, methods of imaging, or methods related to fertility, contraceptive, andropause and muscle or bone mass uses.

The Licensed Process shall mean any process which is covered in whole or in part by a Valid Claim of the Licensed Patents.

The Licensed Product shall mean any product that is covered in whole or in part by a Valid Claim of the Licensed Patents; or is manufactured by using a process or is employed to practice a process which is covered in whole or in part by a Valid Claim of the Licensed Patents.

Patents relate toremifene for the reduction in the incidence of prostate cancer in men with high grade PIN and its composition of matter and method of use patents and patent applications relating to Andarine, Ostarine and Prostarine.

Prostarine is used for the treatment of benign prostatic hyperplasia; and andromustine, an anticancer product candidate for hormone refractory prostate cancer.

Acapodene is an antineoplastic hormonal agent primarily used in the treatment of advanced breast cancer.

Ostarine is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc for the treatment of conditions such as muscle wasting and osteoporosis.

Field of Use
Licensee is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutics primarily related to the treatment of serious men’s health conditions.

Licensee will be able to use these microRNAs to advance multiple research and development programs targeting new microRNA-based diagnostic tools for a variety of diseases.

IPSCIO Record ID: 178918

License Grant
The University hereby grants to Licensee, to the extent it has the legal right to do so, an exclusive license under Universitys Patent Rights and University Technology to make, have made, use, and sell Licensed Products and to practice Licensed Method in the Territory during the term of this Agreement.
License Property
Certain inventions disclosed under UC Case No. 88-196-1,-2,-3, generally characterized as Method of Treating Tumors using Illudin Analogs, hereinafter collectively referred to as the 'Invention,' were made in the course of research at the University.

Illudin Analogs' shall mean illudofulvene, illudofulvene dimers, and 6-hydroxymethylilludofulvene; including derivatives thereof such as those disclosed and claimed in U.S. Patent Application Number 08/276169, filed July 15, 1994.

Universitys Patent Rights means all pending or issued U.S. and foreign patents and patent applications, owned by The University, including based on the subject matter claimed in or covered by U.S. Patent Application Serial Numbers 416,395 filed October 3, 1989 (now abandoned), 606,511 filed October 31, 1990 or 015,179 filed February 9, 1993 and patent applications added to this Agreement pursuant to the provisions of the Research Agreements.

Universitys Technology means all information and physical objects related to the Invention or Licensed Product.

Licensed Product means any material or product or kit, or any service, process or procedure that either (1) is covered by Universitys Patent Rights or whose manufacture, use, or sale would constitute, but for the license granted to Licensee pursuant to this Agreement, an infringement of any claim within Universitys Patent Rights or (2) is developed, made, used, sold, registered, or practiced using Universitys Technology or Licensed Method or which may be used to practice the Licensed Method, in whole or in part.

Field of Use
This agreement pertains to the drug industry relating to the method of Treating Tumors.

IPSCIO Record ID: 253982

License Grant
Licensor grants an exclusive license, under the Licensor Technology to develop, use, sell, offer for sale, import and/or export Licensed Products in the Territory and in the Field, and make and have made Licensed Products in the Territory for such development, use, sale, offering for sale, importation and/or exportation.

Licensor grants to Licensee, a perpetual, non-exclusive license under the Licensor Technology for Licensees research purposes only.

License Property
Licensor owns or possesses certain patent rights and know-how with respect to motilin agonist compounds.

GI Indication means diseases, disorders or impairments of the gastrointestinal tract, including the esophagus, stomach, pancreas, small and large intestines, colon, and gall bladder.

GI Product means a Licensed Product that has been Approved in a GI Indication.

The compound is 9O-(N-methylamidomethyl)-Ndesmethyl-N-isopropyl-(9S)-9-dihydroerythromycin A.

The patents are for Motilide Compounds, Method for Evaluating Therapeutic Efficacy,  ll-Deoxy-6,9-ether Erythromycin Compounds,  N-Desmethyl-N-substituted-11-deoxyerythromycin Compounds, and,  9-Desoxoerythromycin Compounds as Prokinetic Agents.

Motilin, a hormone that is secreted by the small intestine, stimulates gastrointestinal motility (movement). Erythromycin, a polyketide best known for its antibiotic activity, is an agonist of the motilin receptor that enhances esophageal motility in GERD patients and accelerates gastric emptying in patients with diabetic gastroparesis.

Field of Use
The agreement includes Licensor's clinical candidate, KOS-2187 and related compounds. KOS-2187 has demonstrated improved gastric emptying in preclinical studies and may have therapeutic benefit in gastrointestinal diseases such as gastro- esophageal reflux disease (GERD), or diabetic gastroparesis (delayed gastric emptying).

Licensee believes that the mechanism of action of KOS-2187 and its demonstrated activity as a prokinetic agent are significant indications of its potential as a new approach for the treatment of gastrointestinal diseases.

IPSCIO Record ID: 344572

License Grant
Licensor of Japan grants an exclusive license, including the right to grant sublicenses, under the Licensed Patent Rights, Licensed Technology and Know-how to research, Develop, have Developed, manufacture, have manufactured, use, have used, sell, offer for sale, have sold, import, have imported, export and have exported, Licensed Product in the Territory, for any and all uses within the Licensed Field.
License Property
Licensors Technology includes Technology and information developed for the clinical development of  xxx5500; Licensors Drug Master File;  non-audited reports of clinical trials of KRN5500 in Japan; pre-clinical data on KRN5500, including acute, subchronic and chronic toxicity studies; Other pre-clinical data of Licensors as agreed to;  and, National Cancer Institutes IND and clinical data, including but not limited adverse event and serious adverse event reports, pharmacokinetic and pharmacodynamic data and relevant correspondence with the FDA.

Drug Substance  shall mean bulk active xxx5500.  Intermediates of xxx5500 shall mean SAN and TDG.

xxx5500 shall mean 6-[2-Deoxy-4-[(2E, 4E) tetradecadienoylglycyl]amino-L-glycero-B Lmannoheptopyranosyl]amino-9H-purine; NSC number NSC 650426.

SAN means Spicamycinaminonucleoside-6-amino-[L-mannoheptopyranosyl]amino-9H-purine.

TDG means Tetradecadienoylglycine.

Field of Use
Licensed Field shall mean the treatment of pain and central and peripheral nervous system conditions or diseases.

IPSCIO Record ID: 204320

License Grant
The Licensor, of England and Wales, grants an exclusive, worldwide, sub-licensable license under the Licensed Rights to develop, make, have made, use, import, sell, distribute, have sold and offer for sale Licensed Products for all applications and for all uses.
License Property
Licensor has a technology comprising a product known as BGC-0945 which, subject to further development, is intended to be used in the field of oncology.  BGC-0945 is [N-{N-{4-[N-{2-hydroxymethyl-4-oxo-3,4, 7,8-tetrahydro-6H-cy clopenta[g]quinazolin-6-yI)-N-(prop-2-ynyl)amino ]benzoyl }-L-y -glutamyl}-o-glutamic acid] or any salts, esters, racemates, stereoisomers, crystalline polymorphs, hydrates, solvates, or other acids thereof.

BGC 945 (ONX 0801) is designed to work by combining two proven approaches to improving outcomes for cancer patients. These include receptor-mediated targeting of tumor cells and inhibition of thymidylate synthase, a key enzyme involved in cell growth and division. BGC 945 targets malignant cells that overexpress the alpha-folate receptor, which is located on the cell's surface. Once BGC 945 enters the cell via this receptor, the compound inhibits, or switches off, thymidylate synthase (TS).

Field of Use
The Licensee is in the business of developing and commercializing anticancer therapies.

IPSCIO Record ID: 279383

License Grant
The Israeli Licensor grants an exclusive, even as to Licensor, worldwide license, with the right to sublicense through multiple tiers of sublicense, under the Licensed Technology and Research Technology to research, develop, make, have made, use, sell, offer for sale, have sold and import Licensed Products and Additional Products in the Field.
License Property
The research is for Novel compounds for treatment and as Disease-modifying agents in alzheimers and related CNS & PNS Diseases.

The patents relate to AF150(S) and Congeners, and, AF267B and Congeners, and, AF292 and Congeners.

Licensed Compound shall mean the compound known as AF292 and its isomers, salts, esters and derivatives.

The central nervous system (CNS) is the part of the nervous system consisting of the brain and spinal cord. The peripheral nervous system (PNS) is one of two components that make up the nervous system of bilateral animals, with the other part being the central nervous system (CNS).

Field of Use
The Field shall mean all therapeutic uses.  The compounds for patented drugs are for treatment, prevention and/or diagnosis of nervous system disorders.

License relates to muscarinic agonist assets including its lead drug candidate for Alzheimer’s Disease, or AD, NGX267, and NGX292.

IPSCIO Record ID: 146617

License Grant
The Licensor, a University, and the Co-owners hereby grant to the Company a sole and exclusive, worldwide license in all fields of use to practice under the Patent Rights and to utilize the Know-how, and to make, have made, use, lease and/or sell the Licensed Products and to practice the Licensed Processes, to the full end of the term for which the Patent Rights are granted, unless sooner terminated as hereinafter provided.

The Licensor grants to the Company the right to grant sublicenses to third- parties.

License Property
The Licensor is the owners of Patents and U.S. Patent Applications 08/620/969, 08/255/190, and 08/661/923.
Field of Use
The patents relate to chemotherapy and the agreement is for all fields of use.

IPSCIO Record ID: 203339

License Grant
The Licensor of Finland grants to Licensee an exclusive right and license, with the right to grant sublicenses under Licensor Patent Rights and Know-How, to develop, use, have used, sell, have sold, import, market and distribute the Product in the Field in the Licensee Territory, except in the Licensor Field in the Licensor Territory; and a non-exclusive right and license, with the right to grant sublicenses, under the Licensor Patents and Know-How, to perform research and preclinical development activities, using the Powder to be provided to Licensor, except in the Licensor Field in the Licensee Territory.
License Property
The Product shall mean any pharmaceutical product for human use within the Field containing Toremifene as a therapeutically active ingredient.

The Fareston Product shall mean the Orion Product in 60 mg tablet form containing Toremifene that was promoted in the USA under the brand name Fareston by Shire prior to the Restatement Date for use in the Breast Cancer Field.

Toremifene shall mean [tore mi f ene citrate and/or the Z-isomer of 4-chloro-1, 2 diphenyl-1-(4-(2-(N,N-dimethylamino)-ethoxy) – phenyl]- 1 -butene].

Field of Use
The field means all uses of a Product in humans, with a current use of treatment of prostate cancer. The Parties expressly acknowledge that the use of Product in the field of animal health is excluded from the scope of this Agreement.

IPSCIO Record ID: 70207

License Grant
This worldwide exclusive license agreement with the Israeli Licensor, the technology transfer company of the University, for the rights to a novel, first-in-class, photodynamic therapy that utilizes safe visible light for activation, referred to as SGX301.
License Property
SGX301 is a novel, first-in-class photodynamic therapy using a potent photosensitizer, synthetic hypericin, that is topically applied and activated by safe visible fluorescent light. This treatment avoids the risk of secondary malignancies (including melanoma) inherent with the frequently employed DNA-damaging chemotherapeutic drugs and other photodynamic therapies that are dependent on ultraviolet A (UVA) light exposure. Topical, synthetic hypericin has demonstrated safety in a Phase 1 clinical study in healthy volunteers.  In a Phase 2, placebo-controlled, clinical study in patients with cutaneous T-cell lymphoma (CTCL), the drug was safe, well tolerated, and effective in ameliorating the skin lesions.

Cutaneous T-cell lymphoma (CTCL) is a class of non-Hodgkin’s lymphoma (NHL), a type of cancer of the white blood cells that are an integral part of the immune system.

In addition to issued and pending patents, we also have “Orphan Drug” designations for SGX301 in the U.S.

The exclusive license includes rights to several issued US patents, including U.S. patent numbers 6,867,235 and 7,122,518, among other domestic and foreign patent applications.

Field of Use
Licensee is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

IPSCIO Record ID: 203383

License Grant
The Licensor of Finland grants an exclusive right and license, with the right to grant sublicenses, under Licensor Patent Rights and Know-How, to develop, use, have used, sell, have sold, import, market and distribute the Product in the North American Territory and in Japan in the Field;
– a non-exclusive right and license, with the right to grant sublicenses, under Licensor Patent Rights and
Licensor Know-How, to develop, use, have used, sell, have sold, import, market and distribute the Product in the ROW Territory for exclusive use in the Field;
– a non-exclusive license, under the Licensor Patents and Know-How, to perform research and preclinical development activities using the Powder.
License Property
The product means any pharmaceutical product for human use within the Field containing Toremifene as a therapeutically active ingredient.

Toremifene' shall mean [toremifene citrate and/or 4-chloro-l, 2 diphenyl-1-(4(2-(N,N-dimethylamino)-ethoxyl) – phenyl] -I-butene].

Toremifene is a selective estrogen receptor modulator (SERM) of the triphenylethylene group related to tamoxifen which opposes the actions of estrogens like estradiol in the body and is approved for use in the treatment of advanced (metastatic) breast cancer.

Field of Use
The field means the prevention and treatment of prostate cancer, which shall mean for purposes hereof preventing prostate carcinogenesis; suppressing or inhibiting prostate cancer; reducing the risk of developing prostate cancer; increasing the survival rate of a subject with prostate cancer; and treating prostate cancer.

IPSCIO Record ID: 383608

License Grant
Licensor of Japan grants an exclusive right and license in the Field in the Territory, with the right to grant sublicenses, under the Licensor Technology,
— to develop the API and Product;
— to make, have made, use, import and export the API for the purpose of making, having made, using, offering for sale, selling, marketing, distributing, importing and exporting the Product; and
— to make, have made, use, offer for sale, sell, market, distribute, import and export the Product.
License Property
Licensor owns, and/or has exclusive rights to, the Licensor Technology in existence as of the Effective Date relating to the API /Active Pharmaceutical Ingredients, known as tesetaxel, and Product.

Tesetaxel is an orally administered taxane being investigated as a chemotherapy agent for various types of cancer, including breast cancer, gastric cancer, colorectal cancer, and other solid tumors.

Product means any oral pharmaceutical preparations containing only API as the active ingredient.

USP and its corresponding patents and patent applications*
Country Appln. No. Date of filing Patent No.
U.S.A. 08/945276 1996.04.25 US6075140
U.S.A. 09/759378 2001.01.16 US6545151
U.S.A. 10/091023 2002.03.06 US6677456
U.S.A. 10/469918 2002.03.04 US7126003
U.S.A. 10/495437 2002.11.29 us 2005/0070579
U.S.A. 11/579140 2005.04.27 US2007/0167630

Field of Use
Tesetaxel has completed Phase 2 trials in a number of cancer types and the drug has shown definite evidence of antitumor activity. Tesetaxel may also be associated with a lower incidence of peripheral nerve damage, a common side effect of taxanes.

IPSCIO Record ID: 367579

License Grant
Licensor hereby grants to Licensee, during the Term, an exclusive (subject to Licensor’s retention of certain rights as set forth) royalty-bearing, worldwide license or sublicense (with respect to Licensor Technology and Licensor Patent Rights licensed by third parties to Licensor), with the right to grant sublicenses solely as provided in this Agreement, under Licensor Technology, Licensor Patent Rights and Licensor’s interest in Joint Patent Rights and Joint Technology to make, have made, use, sell, offer for sale and import Products in the Territory.
License Property
STA-4783 means the compound Controlled by Licensor and described more fully in the Agreement.

Indication means any human disease or condition which can be treated, prevented, cured or the progression of which can be delayed.  For purposes of the payment of milestones, with respect to Licensor’s Development Opt-Out Right and with respect to the definition of New Indication, the broadening of use for a Product for a particular Indication, for example, the extension of the use of a Product from treating Stage IV metastatic melanoma to use as an adjuvant treatment for melanoma and/or the approval of a Product as a first line therapy after being approved as a second line therapy for treatment of the same disease or condition shall not be deemed to be separate Indications.

Collaboration Compound means, collectively (a) STA-4783; (b) any  prodrug of STA-4783; (c) any  pharmaceutically active human metabolite of STA-4783; and (d) any other bis thiohydrazide amide isomer, ester, salt, hydrate, solvate and/or polymorph of STA-4783 and/or any of their prodrugs and/or metabolites.  For purposes of this definition, the term Collaboration Compound shall include all Class i Covered Compounds and Class 2 Covered
Compounds not otherwise described in Agreement only to the extent the Parties agree to conduct Development of such Class 1 Covered Compounds or Class 2 Covered Compounds under this Agreement.  As used herein, an isomer of a compound is a positional or conformational variant having the same molecular formula as the compound.

Product means any pharmaceutical or medicinal item, substance, formulation or dosage for sale by prescription, over-the-counter, or any other method, which is comprised of or contains a Collaboration Compound (whether or not such Collaboration Compound is the sole active ingredient).  For purposes of clarity, Product includes Co-Commercialized Products and Royalty-Bearing Products.

Patent Rights
6,800,660 – Taxol enhancer compounds
7,037,940 – Taxol enhancer compounds
6,924,312 – Taxol enhancer compounds

Field of Use
Field of use is for treatment of cancer such as melanoma.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.